|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
盐酸噻吩诺啡片预防阿片类依赖者脱毒后复吸有效性与安全性的多中心、双盲、随机对照II期临床研究
通过评价盐酸噻吩诺啡片在阿片类依赖者脱毒后预防复吸的有效性与安全性,为后续试验给药方案确定提供科学依据.
应用盐酸丁丙诺啡片诱导引入盐酸噻吩诺啡片用于阿片类依赖防复吸探索性研究方案
确定通过丁丙诺啡舌下片脱毒/诱导,再引入盐酸噻吩诺啡片的临床桥接方案,为噻吩诺啡控制阿片类依赖复吸的临床研究做准备。
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅱb Clinical Trial of Thienorphine Hydrochloride Tablets for the Efficacy, Safety, and Optimal Dosing of Relapse Prevention After Opioid Dependence Detoxification
Opioid addiction is common worldwide. Thienorphine hydrochloride is a newly partial opioid receptor agonist drugs. It's affinity with opioid receptors was much higher than opioids, which could effectively prevents opioid dependence by stop opioids competition for opioid receptors and causing opioid dependence. The aim of this research was to determine whether thienorphine hydrochloride would reduce opioid use and better preventing relapse among opioid addicts.
100 项与 北京紫都宏业科技发展有限公司 相关的临床结果
0 项与 北京紫都宏业科技发展有限公司 相关的专利(医药)
100 项与 北京紫都宏业科技发展有限公司 相关的药物交易
100 项与 北京紫都宏业科技发展有限公司 相关的转化医学